Modality
Vaccine
MOA
CDK4/6i
Target
BET
Pathway
Innate Imm
GAParkinson'sPsoriasis
Development Pipeline
Preclinical
~Jul 2013
→ ~Oct 2014
Phase 1
~Jan 2015
→ ~Apr 2016
Phase 2
~Jul 2016
→ ~Oct 2017
Phase 3
~Jan 2018
→ ~Apr 2019
NDA/BLA
Jul 2019
→ Feb 2027
NDA/BLACurrent
NCT07254830
676 pts·Parkinson's
2019-07→2027-02·Recruiting
676 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-1611mo awayPh3 Readout· Parkinson's
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-02-16 · 11mo away
Parkinson's
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07254830 | NDA/BLA | Parkinson's | Recruiting | 676 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| NBI-3153 | Neurocrine | Approved | Aβ | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF |